208 related articles for article (PubMed ID: 24909169)
1. Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells.
Kobayashi T; Masoumi KC; Massoumi R
Oncogene; 2015 Apr; 34(17):2251-60. PubMed ID: 24909169
[TBL] [Abstract][Full Text] [Related]
2. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
3. Identification of optineurin as an interleukin-1 receptor-associated kinase 1-binding protein and its role in regulation of MyD88-dependent signaling.
Tanishima M; Takashima S; Honda A; Yasuda D; Tanikawa T; Ishii S; MaruYama T
J Biol Chem; 2017 Oct; 292(42):17250-17257. PubMed ID: 28882891
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.
Jono H; Lim JH; Chen LF; Xu H; Trompouki E; Pan ZK; Mosialos G; Li JD
J Biol Chem; 2004 Aug; 279(35):36171-4. PubMed ID: 15226292
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
6. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Trompouki E; Hatzivassiliou E; Tsichritzis T; Farmer H; Ashworth A; Mosialos G
Nature; 2003 Aug; 424(6950):793-6. PubMed ID: 12917689
[TBL] [Abstract][Full Text] [Related]
7. The K48-K63 Branched Ubiquitin Chain Regulates NF-κB Signaling.
Ohtake F; Saeki Y; Ishido S; Kanno J; Tanaka K
Mol Cell; 2016 Oct; 64(2):251-266. PubMed ID: 27746020
[TBL] [Abstract][Full Text] [Related]
8. CYLD and the NEMO Zinc Finger Regulate Tumor Necrosis Factor Signaling and Early Embryogenesis.
Zhao Y; Ma CA; Wu L; Iwai K; Ashwell JD; Oltz EM; Ballard DW; Jain A
J Biol Chem; 2015 Sep; 290(36):22076-84. PubMed ID: 26224629
[TBL] [Abstract][Full Text] [Related]
9. Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.
Takami Y; Nakagami H; Morishita R; Katsuya T; Hayashi H; Mori M; Koriyama H; Baba Y; Yasuda O; Rakugi H; Ogihara T; Kaneda Y
Am J Pathol; 2008 Mar; 172(3):818-29. PubMed ID: 18245814
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation.
Reiley W; Zhang M; Wu X; Granger E; Sun SC
Mol Cell Biol; 2005 May; 25(10):3886-95. PubMed ID: 15870263
[TBL] [Abstract][Full Text] [Related]
12. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC
Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
[TBL] [Abstract][Full Text] [Related]
13. Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma.
Chu L; Gu J; He Z; Xiao T; Liu X
Cancer Biol Ther; 2006 Jun; 5(6):615-22. PubMed ID: 16627981
[TBL] [Abstract][Full Text] [Related]
14. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.
Uematsu A; Kido K; Takahashi H; Takahashi C; Yanagihara Y; Saeki N; Yoshida S; Maekawa M; Honda M; Kai T; Shimizu K; Higashiyama S; Imai Y; Tokunaga F; Sawasaki T
J Biol Chem; 2019 Sep; 294(38):14135-14148. PubMed ID: 31366726
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.
Yoshida H; Jono H; Kai H; Li JD
J Biol Chem; 2005 Dec; 280(49):41111-21. PubMed ID: 16230348
[TBL] [Abstract][Full Text] [Related]
16. Competition between TRAF2 and TRAF6 regulates NF-kappaB activation in human B lymphocytes.
Zhang W; Zhang X; Wu XL; He LS; Zeng XF; Crammer AC; Lipsky PE
Chin Med Sci J; 2010 Mar; 25(1):1-12. PubMed ID: 20449947
[TBL] [Abstract][Full Text] [Related]
17. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
Kovalenko A; Chable-Bessia C; Cantarella G; Israël A; Wallach D; Courtois G
Nature; 2003 Aug; 424(6950):801-5. PubMed ID: 12917691
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFα-induced cancer cell migration.
Xiao N; Li H; Luo J; Wang R; Chen H; Chen J; Wang P
Biochem J; 2012 Feb; 441(3):979-86. PubMed ID: 22029577
[TBL] [Abstract][Full Text] [Related]
19. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
Almeida S; Maillard C; Itin P; Hohl D; Huber M
J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586
[TBL] [Abstract][Full Text] [Related]
20. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]